Premium
Acute myeloid leukaemia after treatment with 90 Y‐ibritumomab tiuxetan for follicular lymphoma
Author(s) -
Focosi Daniele,
Cecconi Nadia,
Boni Giuseppe,
Orciuolo Enrico,
Galimberti Sara,
Petrini Mario
Publication year - 2008
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.849
Subject(s) - radioimmunotherapy , ibritumomab tiuxetan , myeloid leukaemia , medicine , follicular lymphoma , lymphoma , myeloid , oncology , myelodysplastic syndromes , nuclear medicine , immunology , bone marrow , monoclonal antibody , antibody
We report here a patient with relapsed follicular lymphoma who developed secondary acute myeloid leukaemia 15 months after radioimmunotherapy (RIT) with 90 Y‐ibritumomab tiuxetan, the fifth described case to date. We review the literature for the potential causal relationship between RIT and secondary myelodysplastic syndromes/acute myeloid leukaemia. Copyright © 2008 John Wiley & Sons, Ltd.